These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38793610)
21. Anti-HIV Activities and Mechanism of 12-O-Tricosanoylphorbol-20-acetate, a Novel Phorbol Ester from Ostodes katharinae. Chen H; Zhang R; Luo RH; Yang LM; Wang RR; Hao XJ; Zheng YT Molecules; 2017 Sep; 22(9):. PubMed ID: 28885587 [TBL] [Abstract][Full Text] [Related]
22. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212 [TBL] [Abstract][Full Text] [Related]
23. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface. Letko M; Booiman T; Kootstra N; Simon V; Ooms M Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364 [TBL] [Abstract][Full Text] [Related]
24. Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes. Reddy K; Ooms M; Letko M; Garrett N; Simon V; Ndung'u T AIDS; 2016 Jul; 30(11):1723-9. PubMed ID: 27064995 [TBL] [Abstract][Full Text] [Related]
25. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway. Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557 [TBL] [Abstract][Full Text] [Related]
26. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication. Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381 [TBL] [Abstract][Full Text] [Related]
27. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088 [TBL] [Abstract][Full Text] [Related]
28. An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA. Widera M; Erkelenz S; Hillebrand F; Krikoni A; Widera D; Kaisers W; Deenen R; Gombert M; Dellen R; Pfeiffer T; Kaltschmidt B; Münk C; Bosch V; Köhrer K; Schaal H J Virol; 2013 Mar; 87(5):2707-20. PubMed ID: 23255806 [TBL] [Abstract][Full Text] [Related]
29. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G. Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493 [TBL] [Abstract][Full Text] [Related]
30. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027 [TBL] [Abstract][Full Text] [Related]
31. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. Ao Z; Yu Z; Wang L; Zheng Y; Yao X PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671 [TBL] [Abstract][Full Text] [Related]
32. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity. Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180 [TBL] [Abstract][Full Text] [Related]
33. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G. Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403 [TBL] [Abstract][Full Text] [Related]
34. Structural basis for HIV-1 antagonism of host APOBEC3G via Cullin E3 ligase. Ito F; Alvarez-Cabrera AL; Liu S; Yang H; Shiriaeva A; Zhou ZH; Chen XS Sci Adv; 2023 Jan; 9(1):eade3168. PubMed ID: 36598981 [TBL] [Abstract][Full Text] [Related]
35. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors. Chesarino NM; Emerman M J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta. Miyagi E; Welbourn S; Sukegawa S; Fabryova H; Kao S; Strebel K J Virol; 2020 Mar; 94(7):. PubMed ID: 31941780 [TBL] [Abstract][Full Text] [Related]
37. Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection. Thangavelu PU; Gupta V; Dixit NM Virology; 2014 Jan; 449():224-8. PubMed ID: 24418556 [TBL] [Abstract][Full Text] [Related]
38. Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction. Duan S; Yu X; Wang C; Meng L; Gai Y; Zhou Y; Gu T; Yu B; Wu J; Yu X J Virol; 2022 Sep; 96(17):e0055522. PubMed ID: 35950859 [TBL] [Abstract][Full Text] [Related]
39. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. Chaipan C; Smith JL; Hu WS; Pathak VK J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy. Green LA; Liu Y; He JJ J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]